In fact, the preliminary data of the clinical trial that evaluated the combination of anti-PD-L1 and MEK inhibitor, showed promising results with efficacy of this combination also in microsatellite stable (MSS) non-hypermutated CRC patients [41]. Here, CD274 is linked to colorectal carcinoma.